US Executive Officer Management Changes SEC — July 15, 2026

15-07-2026

Hycroft Mining Holding Corporation announced the appointment of Michael Deal as Senior Vice President and Chief Operating Officer, effective August 24, 2026. Mr. Deal brings over 20 years of operating and technical leadership experience in North American gold and silver operations, including roles at First Majestic Silver, Nevada Gold Mines, and Newmont Corporation. The company highlighted his expertise in sulfide processing and refractory ore treatment as directly relevant to advancing the Hycroft Mine, particularly the high-grade silver systems Brimstone and Vortex.

• · Michael Deal is a Registered Member and Qualified Person (QP) with the Society for Mining, Metallurgy & Exploration (SME).
• · He holds a Bachelor of Science in Chemical Engineering with a minor in Economics from the Colorado School of Mines and an MBA from Arizona State University.
• · Mr. Deal serves on the SME Foundation Board of Directors and has previously served on the Nevada Mining Association Board of Directors and the Nevada Mineral Processing Division Board.
• · The company is advancing to the next phase of operations for processing sulfide mineralization at the Hycroft Mine.

15-07-2026

Cytek Biosciences disclosed the departure of Chief Legal Officer and Corporate Secretary Valerie Barnett, effective June 29, 2026, and entered into a severance agreement and a consulting agreement for transition support. The severance includes a lump sum payment of $365,775.12 and COBRA premium coverage, with enhanced change-in-control benefits if a transaction occurs within three months. The consulting agreement provides for up to 10 hours per week at $1,000 per hour through August 31, 2026, with continued equity vesting.

• · Valerie Barnett's position terminated on June 29, 2026; severance agreement signed July 9, 2026.
• · COBRA premiums covered through earlier of April 30, 2027 or new employer coverage.
• · In a change-in-control within 3 months, Barnett would receive 18 months base salary plus 2026 bonus target, with prior severance credited.
• · Change-in-control also triggers COBRA premium coverage through January 31, 2028 and full acceleration of outstanding equity awards.
• · Consulting agreement effective July 10, 2026, initial term through August 31, 2026, with possible extension.
• · During consulting term, previously granted equity awards under 2021 Equity Incentive Plan continue to vest.

15-07-2026

Gossamer Bio, Inc. filed an 8-K on July 15, 2026, reporting that at a special meeting of stockholders held on July 14, 2026, shareholders approved an amendment to the company's Amended and Restated Certificate of Incorporation. The amendment increases the authorized capital stock from an unspecified prior amount to 4,070,000,000 shares, consisting of 4,000,000,000 shares of Common Stock and 70,000,000 shares of Preferred Stock. The filing also covers items related to director/officer changes (Items 5.02, 5.03, 5.07, 9.01), but the exhibit only details the charter amendment; no specific officer departures or elections are described in the provided content.

• · The amendment was approved at a special meeting of stockholders held on July 14, 2026.
• · The certificate of amendment was executed on July 14, 2026, and filed with the Delaware Secretary of State.
• · The company was originally known as FSG Bio, Inc. and filed its original Certificate of Incorporation on October 26, 2015.
• · The par value per share for both Common and Preferred Stock is $0.0001.

15-07-2026

Vaxcyte, Inc. announced the retirement of board member Heath Lukatch effective July 16, 2026, and the appointment of John Markels as a Class II director and member of the Audit and Compensation Committees, effective the same day. Dr. Lukatch's departure was not due to any disagreement with the company. The annual equity grant for directors is currently set at $430,000.

• · Dr. Lukatch served on the Board for over eight years.
• · Dr. Markels was appointed upon recommendation of the Nominating and Corporate Governance Committee.
• · Dr. Markels qualifies as an independent director under Nasdaq Rule 5605(a)(2).
• · No arrangements or understandings exist between Dr. Markels and any other person regarding his selection as a director.
• · No reportable transactions under Item 404(a) of Regulation S-K exist between the company and Dr. Markels.
• · Dr. Markels will receive compensation per the company's non-employee director compensation program, with the annual equity grant value currently set at $430,000.
• · The company entered into its standard form of indemnification agreement with Dr. Markels.

15-07-2026

On July 10, 2026, Ensysce Biosciences, Inc. received a resignation notice from Jeffrey Millard, its Chief Operating Officer, effective immediately. The departure is a senior management change, but no financial details or replacement plans were disclosed in the filing.

• · The resignation was effective immediately on July 10, 2026.
• · No reason for departure or successor was mentioned in the filing.
• · The filing was made under Item 5.02 (Departure of Directors or Certain Officers) and Item 9.01 (Financial Statements and Exhibits).

15-07-2026

Mobia Medical, Inc. appointed Dr. Reza Zadno as a new independent Class III director on July 14, 2026, expanding the board from six to seven members. Dr. Zadno brings extensive experience as former CEO of PROCEPT BioRobotics and Avedro, and will serve on the Compensation Committee. No financial figures or period-over-period comparisons are included in this filing.

• · Dr. Zadno's term as Class III director expires at the 2029 annual meeting.
• · Dr. Zadno served as President and CEO of PROCEPT BioRobotics from February 2020 to September 2025.
• · Dr. Zadno served as President and CEO of Avedro from September 2016 to November 2020.
• · Dr. Zadno has been an Operating Partner at Jolt Capital since February 2026.
• · Dr. Zadno is a Special Advisor to the American Academy of Ophthalmology since January 2024.
• · No transactions between Dr. Zadno and Mobia requiring Item 404(a) disclosure.

15-07-2026

RLI Corp. appointed James H. Bradshaw, Chairman of Gallagher Re North America, to its Board of Directors effective July 15, 2026. Bradshaw brings over 40 years of insurance industry leadership experience. His term expires at the next shareholders' meeting in May 2027, when he will stand for re-election.

• · Bradshaw served as CEO of Gallagher Re North America and its predecessor Willis Re North America for over a decade before becoming Chairman in 2024.
• · Prior to Willis Re, Bradshaw held leadership and underwriting roles at Guy Carpenter and Chubb.
• · RLI's insurance subsidiaries are all rated A++ 'Superior' by AM Best Company.

15-07-2026

The Hartford announced the appointment of Randy Larsen to its Board of Directors, effective September 1, 2026. Larsen, former CEO of AssuredPartners, brings deep insurance industry expertise and will serve on the Finance, Investment and Risk Management Committee and the Nominating and Corporate Governance Committee. The filing contains no financial results or period-over-period comparisons.

• · Larsen served as CEO of AssuredPartners from 2023 through its acquisition by Gallagher in 2025.
• · He will serve on the Finance, Investment and Risk Management Committee and the Nominating and Corporate Governance Committee.
• · Larsen earned a bachelor’s degree in finance from Nebraska Wesleyan University.

15-07-2026

RxSight, Inc. announced a planned leadership transition effective July 20, 2026, appointing Aziz Mottiwala as President and CEO, while founder Ron Kurtz, MD steps down as CEO to become Chief Medical Officer. Dr. Kurtz will also resign from the Board of Directors, with Mr. Mottiwala joining the Board. The company stated it is not updating its previously communicated financial guidance in connection with this announcement.

• · Mr. Mottiwala most recently served as Chief Commercial Officer at Tarsus Pharmaceuticals and previously held the same role at Opiant Pharmaceuticals.
• · Before that, he spent more than a decade at Allergan in senior leadership positions across the eye care franchise.
• · Mr. Mottiwala holds a B.S. in Biochemistry from UC San Diego and an MBA from USC.
• · Dr. Kurtz will resign from the Board of Directors, and Mr. Mottiwala will be appointed to the Board.
• · The company is not updating its previously communicated financial guidance.

15-07-2026

Socket Mobile, Inc. appointed former director Brent MacDonald to its Board of Directors, effective July 13, 2026. MacDonald previously served on the board from 2016 to 2023, and his return expands the board to six members, four of whom are independent. The filing contains no financial results or period-over-period comparisons, so no quantitative performance data is available.

• · Brent MacDonald previously served on Socket Mobile's Board from 2016 to 2023.
• · The appointment was effective July 13, 2026, and announced via press release on July 15, 2026.
• · The board now consists of six members, with four independent directors under Nasdaq listing standards.

15-07-2026

The Dayton Power and Light Company (AES Ohio) appointed Robert Osborn as Controller and principal accounting officer effective July 10, 2026. Sherry Kohan will continue as Vice President and CFO. Mr. Osborn, 44, previously served as Director of Revenue Accounting, Internal Controls and Finance Transformation of AES US Utilities since March 2025 and holds similar officer roles at other AES affiliates. No financial results or period-over-period comparisons are included in this filing.

• · Mr. Osborn previously served as Director of Revenue Accounting, Internal Controls and Finance Transformation of AES US Utilities since March 2025 and Director of Internal Controls and Finance Transformation from August 2024 to February 2025.
• · He also serves as Controller and principal accounting officer of DPL, IPALCO and AES Indiana since July 2026.
• · Prior to rejoining AES in June 2024, Mr. Osborn was Corporate Controller of USIC from July 2023 to June 2024.
• · He initially joined AES in August 2013 and held roles including Assistant Controller of AES US Utilities from March 2021 to July 2023.
• · Mr. Osborn holds a B.S. from Towson University, a Graduate Certificate in Advanced Accounting from University of Maryland Global Campus, an M.B.A. from University of Baltimore, and an M.S. in Finance from Indiana University.
• · AES Ohio does not separately compensate individuals for service as officers or directors; Mr. Osborn participates in AES management compensation plans generally exceeding $120,000 annually.

15-07-2026

IPALCO Enterprises, Inc. appointed Robert Osborn as Controller and principal accounting officer of IPALCO and its subsidiary AES Indiana, effective July 10, 2026. Sherry Kohan will continue as Vice President and CFO, relinquishing the Controller role. Mr. Osborn brings extensive experience from prior roles within AES and other companies, and his compensation exceeds $120,000 annually through AES affiliate plans.

• · Robert Osborn, age 44, previously served as Director of Revenue Accounting, Internal Controls and Finance Transformation of AES US Utilities since March 2025.
• · Mr. Osborn also serves as Controller and principal accounting officer of DPL and AES Ohio since July 2026.
• · He initially joined AES in August 2013 and held various roles including Assistant Controller of AES US Utilities from March 2021 to July 2023.
• · Mr. Osborn holds a B.S. from Towson University, a Graduate Certificate in Advanced Accounting from University of Maryland Global Campus, an M.B.A. from University of Baltimore, and an M.S. in Finance from Indiana University.
• · IPALCO and AES Indiana do not separately compensate officers or board members for their service; compensation is provided through AES affiliate plans.

15-07-2026

American Airlines Group Inc. elected John W. Dietrich, former EVP and CFO of FedEx Corporation, to its board of directors, effective July 15, 2026. Dietrich will serve on the Audit and Finance Committees, bringing 35 years of aviation and air cargo experience. The appointment is a routine board refreshment with no financial impact or negative metrics reported.

• · Dietrich most recently served as EVP and CFO of FedEx Corporation from 2023 to 2026.
• · He previously served as President and CEO of Atlas Air Worldwide and spent over a decade at United Airlines as an attorney.
• · Dietrich currently chairs the National Defense Transportation Association and serves on the boards of AAR Corporation and First Horizon Corporation.
• · American Airlines operates more than 6,000 daily flights to over 350 destinations in more than 60 countries.
• · The airline serves more than 200 million customers annually and employs 130,000 people.
• · American Airlines celebrates its centennial year in 2026.

15-07-2026

Infinity Natural Resources appointed Timothy Dugan to its Board of Directors on July 13, 2026. Dugan brings over 40 years of leadership experience in the Appalachian energy industry, including roles as CEO of Olympus Energy and COO of CNX Resources. The appointment strengthens the Board's operational and strategic expertise as the company executes its long-term growth strategy.

• · Dugan most recently led Olympus Energy through its sale to EQT Corporation.
• · He previously served as EVP and COO of CNX Resources and as a director of CNX Midstream Partners LP.
• · Earlier career includes senior roles at Chesapeake Energy, Equitable Production Company, and Cabot Oil & Gas Corporation.
• · Dugan holds a B.S. in Chemical Engineering from the University of Pittsburgh.

15-07-2026

The Hanover Insurance Group announced CEO succession: John C. Roche will retire as President and CEO on December 31, 2026, and COO Richard W. Lavey has been named CEO-elect to ensure a smooth transition. The company highlighted strong financial position and record operating earnings under Roche's leadership, but no specific financial metrics for the current period were provided in the filing.

• · Roche, 62, joined The Hanover in 2006 and became CEO in 2017.
• · Lavey, 59, joined The Hanover in 2004 and currently serves as COO and president of Hanover Agency Markets.
• · Lavey previously held roles including chief marketing officer, chief growth innovation officer, president of personal lines, and president of northeast region.
• · Lavey is a Phi Beta Kappa graduate of The College of Holy Cross and holds an MBA from Harvard Business School.
• · The company will answer questions at its earnings call on July 29, 2026, and will share strategy update at investor day on September 17, 2026.

15-07-2026

Lamb Weston Holdings amended its 2026 Inducement Stock Plan to reduce the authorized shares from 2,000,000 to 1,538,000 on July 13, 2026, as approved by the Compensation Committee. The plan is used to grant equity to new hires as inducements for employment under NYSE rules.

• · The reduction of authorized shares from 2,000,000 to 1,538,000 represents a decrease of 462,000 shares (23.1%).
• · The plan is intended for individuals not previously employed by the company or returning after a bona fide non-employment period.
• · The amendment was made on July 13, 2026, and the filing was dated July 15, 2026.

15-07-2026

GameSquare Holdings granted 50,000 fully vested RSUs to its COO Amaree Vichairattanawong as a discretionary bonus on July 10, 2026. Separately, the company corrected previously invalid option grants to CEO Justin Kenna (1,045,712 shares) and CFO Michael Munoz (301,249 shares) by issuing new valid options on the same date, with 62.5% vesting immediately and the remainder vesting in one year. The filing highlights a governance correction regarding prior option grants that were not validly issued.

• · The RSUs were granted as a discretionary bonus separate from the COO's employment agreement.
• · The previously reported option awards to Kenna and Munoz (filed July 15, 2025 and amended November 14, 2025) were not validly issued; the new grants correct this.
• · Option vesting: 62.5% vests on July 10, 2026; 37.5% vests on July 10, 2027.

15-07-2026

NewLake Capital Partners announced that David Weinstein will resign from its Board of Directors, effective July 31, 2026. Weinstein, who served as CEO during the company's transition to public markets, has been a board member since the company's founding in 2019. The company expressed gratitude for his contributions and wished him well in future endeavors.

• · David Weinstein was a board member since NewLake's founding in 2019.
• · Weinstein served as CEO during the company's transition to public markets.
• · The resignation is effective July 31, 2026.
• · NewLake owns 34 properties: 15 cultivation facilities and 19 dispensaries, primarily under triple-net leases.

15-07-2026

Jones Soda Co. announced the resignation of director Mark Murray, effective July 13, 2026, which was not due to any disagreement with the company. The board thanked Murray for his service and will evaluate the timing and need for appointing an additional director as part of its governance and succession-planning process.

• · Mark Murray's resignation was effective July 13, 2026.
• · The resignation was not the result of any disagreement with the company regarding operations, policies, accounting principles, financial statement disclosure, or internal controls.
• · The board will evaluate the timing and need for appointing an additional director as part of ongoing corporate governance and succession-planning.

15-07-2026

Celldex Therapeutics disclosed on July 15, 2026 that CFO Sam Martin plans to retire by March 31, 2027, triggering a search for a successor. The announcement provides a long transition period but introduces key-person risk at the finance leadership level.

• · Retirement effective on or about March 31, 2027, providing a ~8.5-month transition period.
• · Sam Martin joined Celldex in April 2009 and has served as CFO since July 2017.
• · The company has initiated a search for a new CFO.
• · Mr. Martin will continue as CFO until his successor begins or March 31, 2027, whichever is earlier.
• · No financial impact or costs associated with the departure were disclosed.
• · Filing includes no financial statements beyond the cover page (Exhibit 104).